Nabisere, R., Musaazi, J., Denti, P., Aber, F., Lamorde, M., Dooley, K. E., . . . Sekaggya-Wiltshire, C. (2020). Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: Study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials.

Nabisere, Ruth, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E. Dooley, Rob Aarnoutse, Derek J. Sloan, and Christine Sekaggya-Wiltshire. "Pharmacokinetics, SAfety/tolerability, and EFficacy of High-dose RIFampicin in Tuberculosis-HIV Co-infected Patients On Efavirenz- or Dolutegravir-based Antiretroviral Therapy: Study Protocol for an Open-label, Phase II Clinical Trial (SAEFRIF)." Trials 2020.

Nabisere, Ruth, et al. "Pharmacokinetics, SAfety/tolerability, and EFficacy of High-dose RIFampicin in Tuberculosis-HIV Co-infected Patients On Efavirenz- or Dolutegravir-based Antiretroviral Therapy: Study Protocol for an Open-label, Phase II Clinical Trial (SAEFRIF)." Trials 2020.